InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,527.45
(
1.67%
)
US TECH 100
18,834.80
(
2.92%
)
Dow Jones
40,964.60
(
0.54%
)
Brent Oil
80.48
(
2.44%
)
Bitcoin
66,432.55
(
0.40%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Whosetosay

Send PM Follow Ignore
Followers 26
Posts 4429
Boards Moderated 0
Alias Born 06/08/2010

Whosetosay

Re: None

Thursday, 03/13/2014 5:56:43 PM

Thursday, March 13, 2014 5:56:43 PM

Post# of 80490
Ariad's funding issues hurt its pipeline in many ways. Read jaybe's post over yonder about LDK's two pIII studies under way for 1st line. Ariad scrubbed '113 1st line studies somewhere along the way.

While '113 is the better drug by far, LDK might edge it out of second patients by being 1st line in patients.

Anyone?

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up